COPENHAGEN, Denmark I September 30, 2014 I DanDrit Biotech A/S (“DanDrit Denmark”), the subsidiary of DanDrit Biotech USA, Inc. (“DanDrit”), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS “San Martino” – IST – National Institute for Cancer Research known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital is principal investigator of the randomized multicenter study.
The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evidence of disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.
“Over the last year,” noted Dr. Eric Leire, DanDrit’s Chief Executive Officer, “DanDrit has focused its efforts on developing MCV for colorectal cancer patients. We intend to continue our efforts to develop a vaccine that we hope can ameliorate the scourge of colorectal cancer.”
About DanDrit
We are a biotechnology company focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer. Our expertise in producing dendritic cells from a patient’s blood is combined with conventional production methods with a goal of making new and advanced vaccines for cancer patients.
SOURCE: DanDrit
Post Views: 80
COPENHAGEN, Denmark I September 30, 2014 I DanDrit Biotech A/S (“DanDrit Denmark”), the subsidiary of DanDrit Biotech USA, Inc. (“DanDrit”), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS “San Martino” – IST – National Institute for Cancer Research known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital is principal investigator of the randomized multicenter study.
The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evidence of disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.
“Over the last year,” noted Dr. Eric Leire, DanDrit’s Chief Executive Officer, “DanDrit has focused its efforts on developing MCV for colorectal cancer patients. We intend to continue our efforts to develop a vaccine that we hope can ameliorate the scourge of colorectal cancer.”
About DanDrit
We are a biotechnology company focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer. Our expertise in producing dendritic cells from a patient’s blood is combined with conventional production methods with a goal of making new and advanced vaccines for cancer patients.
SOURCE: DanDrit
Post Views: 80
